Vectura Group plc Directorate Change (2801A)
28 September 2020 - 7:00PM
UK Regulatory
TIDMVEC
RNS Number : 2801A
Vectura Group plc
28 September 2020
Board Change
Chippenham, UK - 28 September 2020 : Vectura Group plc (LSE:
VEC) ("Vectura" or "the Group") announces that Ms Anne Whitaker is
stepping down from the Board and as an Independent Non-Executive
Director of Vectura. This change will take effect from 30 September
2020.
Ms. Whitaker and the Board have determined, with regret, that it
is appropriate for her to step down in light of potential conflicts
that could arise in the future as a result of her role of Chief
Executive Officer at Aerami Therapeutics.
Bruno Angelici, Chairman of the Board, said: "I would like to
thank Anne for her significant contributions to Vectura since her
appointment in June 2018. On behalf of the all the Board, I wish
her every success in her continuing role at Aerami Therapeutics and
for the future."
Anne Whitaker added: "I have thoroughly enjoyed my role on the
Board of Vectura and am very grateful to Bruno and the entire
management team and Board for the opportunity. Vectura is extremely
well-positioned for the future as a CDMO and I look forward to
seeing the Company achieve success with partnering with
pharmaceutical and biotech companies to make a difference for
patients."
The Nomination Committee has initiated steps to seek an
appropriate additional Independent Non-Executive Director and will
take diversity matters fully into account when reviewing candidates
for this appointment.
- Ends -
For more information, please contact:
Vectura Group plc
David Ginivan - VP Corporate Communications
Elizabeth Knowles - VP Investor +44 (0)7471 352 720
Relations +44 (0)7767 160 565
Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart
/ David Daley +44 (0)20 3709 5700
Notes
About Vectura
Vectura is a provider of innovative inhaled drug delivery
solutions that enable partners to bring their medicines to
patients. With differentiated proprietary technology and
pharmaceutical development expertise, Vectura is one of the few
companies globally with the device, formulation and development
capabilities to deliver a broad range of complex inhaled
therapies.
Vectura has ten key inhaled and eleven non-inhaled products
marketed by partners with global royalty streams, and a diverse
partnered portfolio of drugs in clinical development. Our partners
include Hikma, Novartis, Sandoz (a division of Novartis AG),
Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin
KingYork.
About Aerami
Aerami Therapeutics, currently a customer of Vectura, is a
biopharmaceutical company committed to developing inhaled therapies
for the treatment of pulmonary arterial hypertension and other
severe respiratory diseases.
For further information, please visit Vectura's website at
www.vectura.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOADVLBLBKLEBBL
(END) Dow Jones Newswires
September 28, 2020 05:00 ET (09:00 GMT)
Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2024 to May 2024
Vectura (LSE:VEC)
Historical Stock Chart
From May 2023 to May 2024